Drugs / Granulocyte-colony stimulating factor (G-CSF)
Granulocyte-colony stimulating factor (G-CSF)
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy4 trials | ||||||
| Phase 1 | NCT03471611 Background | Jun 2018 → Oct 2020 | coronary atherosclerosis | Mayo Clinic | Completed | No outcome recorded |
| Phase 2 | NCT00632827 Background | Jul 2008 → Jun 2014 | peripheral T-cell lymphoma, not otherwise specified | University of California, San Francisco | Terminated | No outcome recorded |
| Phase 3 | NCT01767714 Background | Apr 2013 → Nov 2014 | non-Hodgkin lymphoma | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT01164475 Background | Oct 2010 → Feb 2013 | non-Hodgkin lymphoma | Genzyme, a Sanofi Company | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Granulocyte-colony stimulating factor (G-CSF) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01767714 ↗ |
| Modality | Protein / enzyme biologic | “G-CSF is a glycoprotein” NCT00632827 ↗ |
| Route | Subcutaneous | “10 microgram per kilogram (mcg/kg) granulocyte-colony stimulating factor (G-CSF) subcutaneous (SC) injection” NCT01164475 ↗ |